Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Somatostatin Receptor Positive”

58 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 58 results

Testing effectiveness (Phase 2)Study completedNCT02162446
What this trial is testing

68Ga-OPS202 Study for Diagnostic Imaging of GEP NET

Who this might be right for
Gastroenteropancreatic Neuroendocrine Tumors
Ipsen 12
Testing effectiveness (Phase 2)Looking for participantsNCT03145857
What this trial is testing

Evaluate a New Way to Identify/Diagnose Tumours With Somatostatin Receptors Using [68]Ga-HA-DOTATATE and to Ensure it is Safe to Use

Who this might be right for
Neuroendocrine Tumors
AHS Cancer Control Alberta 1,534
Large-scale testing (Phase 3)Study completedNCT01578239
What this trial is testing

A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours

Who this might be right for
Carcinoid Tumor of the Small BowelNeuroendocrine Tumour
Advanced Accelerator Applications 231
Not applicableNo Longer AvailableNCT01980732
What this trial is testing

68Ga DOTA-TATE PET/CT in Somatostatin Receptor Positive Tumors

Who this might be right for
Carcinoid TumorsIslet Cell (Pancreatic NET)Other Neuroendocrine Tumors
Andrei Iagaru
Testing effectiveness (Phase 2)Study completedNCT01869725
What this trial is testing

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

Who this might be right for
Adult MedulloblastomaChildhood MedulloblastomaNeuroblastoma+2 more
Sue O'Dorisio 68
Large-scale testing (Phase 3)Looking for participantsNCT05918302
What this trial is testing

Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.

Who this might be right for
Neuroendocrine TumorsLung Neuroendocrine NeoplasmThymus Neoplasms
Grupo Espanol de Tumores Neuroendocrinos 170
Early research (Phase 1)Study completedNCT04375267
What this trial is testing

177Lu-DOTA-TATE and Olaparib in Somatostatin Receptor Positive Tumours

Who this might be right for
Clinical Trial, Phase INeuroendocrine TumorsThymoma+1 more
Vastra Gotaland Region 18
Testing effectiveness (Phase 2)Looking for participantsNCT07129252
What this trial is testing

Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

Who this might be right for
SST2-positive Neuroendocrine NeoplasmsNeuroendocrine TumorsNeuroendocrine Neoplasm
Crinetics Pharmaceuticals Inc. 150
Testing effectiveness (Phase 2)UnknownNCT05894486
What this trial is testing

Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors

Who this might be right for
Neuroendocrine Tumors
Peking University 40
Large-scale testing (Phase 3)Looking for participantsNCT05884255
What this trial is testing

An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.

Who this might be right for
Advanced Gastroenteropancreatic Neuroendocrine Tumor
Jiangsu HengRui Medicine Co., Ltd. 220
Large-scale testing (Phase 3)Active Not RecruitingNCT05459844
What this trial is testing

A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs

Who this might be right for
Neuroendocrine Tumors
Sinotau Pharmaceutical Group 196
Testing effectiveness (Phase 2)WithdrawnNCT04915144
What this trial is testing

177Lu-DOTATOC for the Treatment of Patients With Somatostatin Receptor Positive NETs

Who this might be right for
Neuroendocrine TumorsCarcinoid TumorPulmonary Carcinoid Tumor+4 more
British Columbia Cancer Agency
Testing effectiveness (Phase 2)Looking for participantsNCT04888481
What this trial is testing

68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors

Who this might be right for
Neuroendocrine Tumors
University of Alberta 600
Large-scale testing (Phase 3)Active Not RecruitingNCT04919226
What this trial is testing

Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE

Who this might be right for
Neuroendocrine Tumors
ITM Solucin GmbH 259
Testing effectiveness (Phase 2)Active Not RecruitingNCT05724108
What this trial is testing

Testing the Effectiveness of an Anti-cancer Drug, Triapine, When Used With Targeted Radiation-based Treatment (Lutetium Lu 177 Dotatate), Compared to Lutetium Lu 177 Dotatate Alone for Metastatic Neuroendocrine Tumors

Who this might be right for
Metastatic Neuroendocrine Tumor
National Cancer Institute (NCI) 94
Early research (Phase 1)Looking for participantsNCT05687123
What this trial is testing

Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors

Who this might be right for
Metastatic Pancreatic Neuroendocrine TumorPancreatic NeoplasmStage III Pancreatic Neuroendocrine Tumor AJCC v8+2 more
National Cancer Institute (NCI) 24
Early research (Phase 1)Study completedNCT00049023
What this trial is testing

Radiolabeled Octreotide in Treating Children With Advanced or Refractory Solid Tumors

Who this might be right for
Brain and Central Nervous System TumorsGastrointestinal Carcinoid TumorIslet Cell Tumor+4 more
O'Dorisio, M S 27
Testing effectiveness (Phase 2)UnknownNCT05880394
What this trial is testing

Study of Dotatate Imaging in Breast Cancer

Who this might be right for
Breast Cancer Stage IV
Hoag Memorial Hospital Presbyterian 30
Testing effectiveness (Phase 2)Study completedNCT03273712
What this trial is testing

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

Who this might be right for
Neuroendocrine TumorsMeningiomaNeuroblastoma+1 more
University of Iowa 39
Large-scale testing (Phase 3)Looking for participantsNCT06784752
What this trial is testing

Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET

Who this might be right for
Somatostatin Receptor Positive (SSTR+)Gastroenteropancreatic Neuroendocrine Tumor (GEP-NET)
Novartis Pharmaceuticals 240
Load More Results